Sanofi (SNY) Q2 2012 Earnings Call July 26, 2012 8:30 am ET Executives Sébastien Martel Christopher A. Viehbacher - Chief Executive Officer, Director and Member of Strategy Committee Hanspeter Spek - President of Global Operations Olivier Charmeil - Senior Vice President of Sanofi Pasteur - Vaccines Division Jerome Contamine - Chief Financial Officer and Executive Vice President Analysts Richard Vosser - JP Morgan Chase & Co, Research Division Michael Leuchten - Barclays Capital, Research Division Tim Anderson - Sanford C. Bernstein & Co., LLC., Research Division Philippe Lanone - Natixis Bleichroeder LLC, Research Division Graham Parry - BofA Merrill Lynch, Research Division Jo Walton - Crédit Suisse AG, Research Division Mark Clark - Deutsche Bank AG, Research Division Peter Verdult - Morgan Stanley, Research Division Vincent Meunier - Exane BNP Paribas, Research Division PresentationOperator
Welcome to the Sanofi 2012 Second Quarter Results Conference Call. I now hand over to Mr. Sébastien Martel and to Mr. Christoph Viehbacher. Sir, please go ahead. . Sébastien Martel Thank you. Hi, everyone, and welcome to our second quarter conference call. As always I must advise you that the information presented today in the call contains forward-looking statements that involve known and unknown risks and uncertainties that may cause actual results to differ materially. So I'd like to please ask you refer to our Form 20-F on file with the SEC and also our Document de Référence for a description of these risk factors. So with me today on the call are Chris Viehbacher, our CEO; Hanspeter Spek, our President of Global Operations; Olivier Charmeil, Senior VP for Vaccines; and Jerome Contamine, our CFO.